Small Molecular Prodrug Amphiphile Self-Assembled AIE Dots for Cancer Theranostics

Cancer Cell-Specific Fluorescent Prodrug Delivery Platforms

Targeting cancer cells with high specificity is one of the most essential yet challenging goals of tumor therapy. Because different surface receptors, transporters, and integrins are overexpressed specifically on tumor cells, using these tumor cell-specific properties to improve drug targeting efficacy holds particular promise. Targeted fluorescent prodrugs not only improve intracellular accumulation and bioavailability but also report their own localization and activation through real-time changes in fluorescence. In this review, efforts are highlighted to develop innovative targeted fluorescent prodrugs that efficiently accumulate in tumor cells in different organs, including lung cancer, liver cancer, cervical cancer, breast cancer, glioma, and colorectal cancer. The latest progress and advances in chemical design and synthetic considerations in fluorescence prodrug conjugates and how their therapeutic efficacy and fluorescence can be activated by tumor-specific stimuli are reviewed. Additionally, novel perspectives are provided on strategies behind engineered nanoparticle platforms self-assembled from targeted fluorescence prodrugs, and how fluorescence readouts can be used to monitor the position and action of the nanoparticle-mediated delivery of therapeutic agents in preclinical models. Finally, future opportunities for fluorescent prodrug-based strategies and solutions to the challenges of accelerating clinical translation for the treatment of organ-specific tumors are proposed.

A biocompatible polyurethane fluorescent emulsion with aggregation-induced emission for targeted tumor imaging

The applications of fluorescence imaging in tumor detection and assistance in tumor resection have become progressively more widespread. Biocompatible fluorescent nanoparticles with high sensitivity and selectivity are a challenge for biological fluorescence imaging. Ligand-mediated targeting of nanoparticles to tumors is an appealing tactic for improving imaging efficiency. Herein, tetraphenyl ethylene (TPE) and phenylboronic acid (PBA) were introduced into polyurethane to synthesize a PU-TPE-PBA (PTP) fluorescent emulsion with aggregation-induced emission (AIE) for targeted tumor imaging. The PTP emulsion with a size of less than 50 nm shows excellent stability and high fluorescence sensitivity (extremely low TPE concentrations of 0.31 μg mL^-1). Since PBA can selectively recognize and bind to sialic acid (SA) which is widely overexpressed in tumor cells, such PTP nanoparticles can be enriched in tumors and retained for longer periods due to enhanced permeability and retention (EPR) as well as active targeting effects. In addition, the PTP emulsion exhibits good biocompatibility and biosafety. Therefore, the novel PTP emulsion is promising for tumor cell imaging.

Boosting the photodynamic therapy of near-infrared AIE-active photosensitizers by precise manipulation of the molecular structure and aggregate-state packing

Organic functional materials have emerged as a promising class of emissive materials with potential application in cancer phototheranostics, whose molecular structures and solid-state packing in the microenvironment play an important role in reactive oxygen species (ROS) generation and the photodynamic therapy (PDT) effect. Clarifying the guidelines to precisely modulate PDT performance from molecular and aggregate levels is desired but remains challenging. In this work, two compounds, TCP-PF6 and TTCP-PF6, with similar skeletons are strategically synthesized, in which a thiophene segment is ingeniously introduced into the molecular backbone of TCP-PF6 to adjust the intrinsic molecular characteristics and packing in the aggregate state. The experimental and theoretical results demonstrate that TTCP-PF6 can form tight packing mode in comparison with TCP-PF6, resulting in efficient cell imaging and enhanced ROS generation ability in vitro and in vivo. The promising features make TTCP-PF6 a superior photosensitizer for PDT treatment against cancer cells by targeting mitochondria. These findings can provide a feasible molecular design for modulating the biological activity and developing photosensitizers with high ROS generation and PDT effect.